WHATISGM
← All articles

World · May 8, 2026

The Hondius Outbreak: What We Actually Know

TL;DR 8 cases (3 confirmed, 5 suspected) of Andes hantavirus linked to the MV Hondius cruise ship. 3 dead, 1 in ICU, 3 evacuated Wednesday. Cases now suspected in 5 countries. 29+ passengers disembarked before the outbreak was known and flew home to countries including Britain, Singapore, and the United States. Contact

TL;DR

  • 8 cases (3 confirmed, 5 suspected) of Andes hantavirus linked to the MV Hondius cruise ship. 3 dead, 1 in ICU, 3 evacuated Wednesday. Cases now suspected in 5 countries.
  • 29+ passengers disembarked before the outbreak was known and flew home to countries including Britain, Singapore, and the United States. Contact tracing is underway across at least a dozen nations.
  • The Andes strain is the only hantavirus known to transmit person-to-person. The 2018–19 Epuyén outbreak in Argentina produced 34 confirmed cases and 11 deaths from a single index case.
  • Argentina is experiencing a surge in hantavirus cases, with mortality rising to nearly one-third of cases — double the five-year average. Researchers attribute this to climate change expanding rodent habitats.
  • The ship is now en route to Spain's Canary Islands. Remaining passengers and crew are under cabin isolation with a 45-day symptom monitoring window.
  • The WHO assesses global risk as low but warns more cases may emerge given the virus's incubation period of up to 6 weeks.

What Is Hantavirus?

Hantaviruses are a family of zoonotic viruses — meaning they live in animals and occasionally spill over into humans. The natural hosts are rodents, and the virus causes them no apparent illness. It simply replicates inside them, quietly, for the animal's entire life.

The virus particles themselves belong to the order Bunyavirales, family Hantaviridae, genus Orthohantavirus. They are enveloped, single-stranded RNA viruses, roughly spherical, 80–120 nanometres in diameter — small enough that several thousand could fit across the width of a human hair. The genome is tripartite: three segments, labelled S (small), M (medium), and L (large), encoding the nucleocapsid protein, the envelope glycoproteins, and the RNA-dependent RNA polymerase, respectively.

This genetic architecture matters for one practical reason: hantaviruses do not reassort — they do not swap gene segments the way influenza viruses do. Reassortment is one of the mechanisms that produces novel pandemic strains in flu. Hantaviruses lack it. Their evolutionary pace is slower. They are what they are.

Two Diseases, One Family

Hantaviruses cause two distinct clinical syndromes in humans, divided roughly by geography:

Haemorrhagic Fever with Renal Syndrome (HFRS) — the Old World form, found across Europe and Asia. Caused by viruses including Hantaan, Seoul, Puumala, and Dobrava. Case fatality rate: 1–15%, varying by strain. Puumala virus, common in northern Europe, kills fewer than 1% of those infected. Hantaan virus, found in China and Korea, kills 5–15%. Between 10,000 and 100,000 HFRS cases occur globally each year, concentrated in China.

Hantavirus Cardiopulmonary Syndrome (HCPS) — also called Hantavirus Pulmonary Syndrome (HPS) — the New World form, found only in the Americas. Caused by viruses including Sin Nombre (North America), Andes (South America), and Laguna Negra (Paraguay, Bolivia). Case fatality rate: 30–60%. This is the much rarer but far deadlier form. The United States has recorded fewer than 1,000 cases since surveillance began in 1993, with a steady 35% fatality rate. South American countries report hundreds of cases annually, with Argentina consistently reporting the highest incidence in Latin America.

The Andes virus is the strain at the centre of the Hondius outbreak. It was first identified in 1995 in southwestern Argentina and shortly afterwards in Chile. Its natural reservoir is the long-tailed pygmy rice rat (Oligoryzomys longicaudatus), a small rodent native to the southern Andes and Patagonian steppe.

How Transmission Works — and Doesn't

The primary transmission route is inhalation. Infected rodents shed virus in their urine, droppings, and saliva. When these materials dry and become disturbed — by sweeping a barn, cleaning a cabin, hiking through undergrowth — the virus becomes aerosolised. A person breathes it in. That is the standard mechanism. Rodent bites are a possible but rare alternative route.

The virus does not spread through casual contact. It does not spread through respiratory droplets across a room. It does not survive long outside a host. These are not small details. They are the reason hantavirus has never caused a pandemic.

The Andes strain, however, has one property that makes it unique among all known hantaviruses: limited person-to-person transmission. This was first documented during a 1996 outbreak in southern Argentina and has since been observed in several clusters in Argentina and Chile. The mechanism is not fully understood, but epidemiological evidence points to close and prolonged contact — household members, intimate partners, and, in a small number of cases, healthcare workers exposed during the prodromal phase before diagnosis. The 2018–19 Epuyén outbreak is the best-studied example: 34 confirmed cases and 11 deaths, all traceable to a single index case who attended a party while pre-symptomatic.

It is important to be precise here. A 2022 systematic review published in Clinical Microbiology and Infection examined all available evidence and found that comparative studies — the strongest level of evidence — do not support person-to-person transmission. The authors concluded that "the balance of the evidence does not support the claim of human-to-human transmission." At the same time, non-comparative studies from Argentina and Chile consistently report clusters consistent with person-to-person spread. The WHO takes the position that "limited human-to-human transmission among close and prolonged contacts" has been documented for Andes virus. The UK Health Security Agency classifies it as an "airborne high consequence infectious disease" requiring strict isolation and enhanced PPE.

The gap between the systematic review and the field epidemiology is not a contradiction. It reflects the difficulty of ruling out a common rodent exposure when clusters occur in communities where rodent contact is ubiquitous. The Hondius outbreak, because it occurred on a ship in the South Atlantic, may help resolve this question. If sequencing confirms person-to-person transmission in an environment where rodent exposure can be excluded, it would be the strongest evidence yet.

What It Does to Humans

HCPS is not a subtle disease. It moves fast, and when it moves, it kills.

The Clinical Course

The disease unfolds in three phases:

Phase 1: Prodromal (Days 1–5). The early symptoms are indistinguishable from a bad flu or a gastrointestinal bug: fever above 38°C, muscle aches — particularly in the large muscle groups: thighs, hips, back, shoulders — headache, dizziness, chills, and in about half of cases, nausea, vomiting, diarrhoea, and abdominal pain. There is nothing in this phase that says "hantavirus." A doctor seeing these symptoms in a returning traveller would test for dengue, for typhoid, for COVID-19. Hantavirus would not make the first-round differential unless the patient volunteered specific exposure history.

Phase 2: Cardiopulmonary (onset Days 4–10). This is where HCPS reveals itself, and it does so with speed that can shock clinicians who have not seen it before. The virus attacks the endothelial cells lining the capillaries, particularly in the lungs. The capillaries become leaky. Fluid pours into the alveolar air sacs. The patient develops a dry cough, then shortness of breath, then acute respiratory distress as the lungs fill. The heart, starved of oxygen and fighting against flooded pulmonary vasculature, begins to fail. The patient goes into cardiogenic shock — the heart can no longer pump enough blood to sustain the body's organs.

This transition, from "flu-like symptoms" to "patient on a ventilator," can happen within hours. The median time from symptom onset to death is 5–6 days. Most deaths occur within 24–48 hours of cardiopulmonary involvement.

Phase 3: Recovery (weeks to months). Patients who survive the cardiopulmonary phase typically recover fully, but the process is slow. Breathing difficulties can persist for up to two years. Renal function returns gradually, marked by a period of increased urination. There is no evidence of re-infection — surviving HCPS appears to confer lifelong immunity.

The Mortality Rate

The case fatality rate for HCPS in the Americas ranges from 30% to 60%, depending on the strain and the quality of supportive care available. Andes virus specifically carries a CFR of approximately 35–50%. For comparison: seasonal influenza kills roughly 0.1% of those infected; COVID-19's infection fatality rate, pre-vaccination, was estimated at 0.5–1%; Ebola Zaire kills 50–90%. Hantavirus sits in a grim middle ground — far deadlier than respiratory viruses, not quite as deadly as the haemorrhagic fevers, but with no vaccine and no specific treatment.

What Kills the Patient

Death in HCPS is typically a cascade. The leaking pulmonary capillaries cause pulmonary oedema — the lungs fill with fluid. This produces hypoxia. The heart, already under attack from the virus (hantavirus directly infects cardiac myocytes), cannot compensate. Cardiogenic shock follows. Organs fail in sequence. The proximate cause of death is usually cardiac arrest secondary to shock, or irreversible respiratory failure.

Laboratory markers that predict death include: falling platelet counts (median 33,500 cells/mL in fatal cases versus 51,500 in survivors), rising haematocrit (blood concentration as fluid leaks from vessels), rising creatinine (kidney involvement), and rising white blood cell counts. High levels of the cytokine IL-6 are associated with severe disease, and deceased patients consistently show higher IL-6 than survivors.

Treatment — or the Lack of It

There is no approved antiviral for HCPS. Ribavirin, a broad-spectrum antiviral, has been tried — it shows in-vitro activity against hantavirus and some efficacy in HFRS — but clinical trials in HCPS have not demonstrated benefit. Favipiravir has shown mixed results in animal models. The standard of care is aggressive supportive management in an intensive care unit: careful fluid resuscitation (too little and the organs fail; too much and the lungs flood faster), vasopressors to maintain blood pressure, mechanical ventilation, and, in severe cases, extracorporeal membrane oxygenation (ECMO).

There is no vaccine for any hantavirus. Several candidates have been tested in Phase 1 and Phase 2 trials — including DNA vaccines and inactivated virus vaccines developed in China and South Korea — but none have reached licensure. The commercial incentive is limited: the total global market for a hantavirus vaccine is measured in the tens of thousands of doses per year, concentrated in rural populations and military personnel.

The one treatment that has shown a signal is convalescent plasma — transfusing blood plasma from survivors, which contains neutralising antibodies. In a small Chilean study, patients who received early convalescent plasma had a lower CFR than historical controls. But the evidence base is thin, and plasma is logistically difficult to deploy in remote outbreak settings.

Pandemic-Level Threat or Just Another Scare?

The short answer: this is not a pandemic. The GAVI vaccine alliance rates hantavirus's pandemic threat as "Low." The WHO's risk assessment for the Hondius outbreak — "low" for the global population — is credible and consistent with the evidence. But the full answer requires understanding why, and what would have to change for the assessment to shift.

Why Hantavirus Cannot Easily Go Pandemic

Transmission biology. Hantavirus does not spread through respiratory droplets or aerosols in the way that SARS-CoV-2, influenza, or measles do. The primary route is environmental — inhaling aerosolised rodent excreta. This is a fundamentally different transmission dynamic from a respiratory virus that moves directly from human to human through the air in a supermarket or on a bus. Even the Andes strain's person-to-person transmission requires "close and prolonged contact" — the WHO's formulation is precise and deliberate.

No asymptomatic spread. Hantavirus patients are most infectious during the prodromal phase, before severe symptoms develop, but there is no evidence of transmission from asymptomatic individuals. This is critical. The single feature that made SARS-CoV-2 uncontrollable was pre-symptomatic and asymptomatic transmission. Hantavirus does not appear to have that feature.

Slow evolution. Hantaviruses have co-evolved with their rodent hosts over millions of years. Their mutation rate is low compared to RNA viruses like influenza or coronaviruses. The tripartite genome does not undergo reassortment. The virus is adapted to its rodent reservoir, not to humans. Sustained human-to-human transmission would require adaptations that have not been observed.

Geographic containment. HCPS requires exposure to specific rodent species with specific geographic ranges. The long-tailed pygmy rice rat lives in the southern Andes and Patagonia. You cannot catch Andes hantavirus in London or New York or Singapore — unless you were exposed in Argentina or Chile, or exposed to someone who was.

Scale. Global hantavirus cases number in the tens of thousands annually — perhaps 100,000 at the upper estimate, concentrated in China and northern Europe. HCPS cases in the Americas number in the hundreds. Compare this to the hundreds of millions of COVID-19 infections worldwide. The denominator is orders of magnitude smaller.

What Would Have to Change for Hantavirus to Become a Pandemic Threat

Three things, all of which are currently not true:

  1. Efficient respiratory transmission. The virus would need to evolve the ability to spread via respiratory droplets or aerosols between humans in casual settings. This would require changes to the viral envelope glycoproteins — the proteins that determine which cells the virus can enter. Such changes are possible in theory but have not been observed in decades of surveillance.

  2. Expanded host range. The virus would need to establish itself in a globally distributed rodent species — or adapt to a new reservoir entirely. Currently, each hantavirus strain is tightly adapted to a single rodent host species.

  3. Asymptomatic transmission. The virus would need to develop the capacity for significant pre-symptomatic or asymptomatic spread. Without this, outbreak clusters can be contained through contact tracing and isolation — as Epuyén demonstrated.

None of these changes are impossible. RNA viruses mutate. But the evolutionary distance between "Andes hantavirus as it exists today" and "Andes hantavirus as a pandemic pathogen" is measured in multiple independent adaptations, each of which would need to occur without breaking the virus's fitness in its rodent reservoir. The probability is low.

The Reasonable Concern

The concern that animates the WHO's alertness — and that should animate ours — is not that hantavirus is about to become the next COVID-19. It is that a virus with a 40% case fatality rate, a six-week incubation period, and a clinical presentation that mimics common illnesses has been dispersed across three continents by an international cruise ship, and the public health architecture that detected it took 21 days to do so.

The Epuyén precedent suggests containment is possible. But Epuyén was a single community. The Hondius passengers are scattered across at least a dozen countries, many of which have no experience with hantavirus and no reason to include it in a differential diagnosis. If secondary cases emerge in countries with less robust surveillance systems than South Africa's NICD, the detection gap could widen further.

The pandemic risk is low. The diagnostic risk — cases that go unrecognised until it is too late — is not. And the preparedness risk — the question of whether the global health architecture can coordinate a multi-country response to an unusual pathogen — is being tested in real time.

What Happened

The MV Hondius, a Dutch-flagged expedition cruise ship operated by Oceanwide Expeditions, departed Ushuaia, Argentina, on 1 April 2026 carrying 147 people — 88 passengers and 59 crew representing 23 nationalities. Its itinerary traced the South Atlantic: Antarctica, South Georgia, Nightingale Island, Tristan da Cunha, Saint Helena, and Ascension Island.

On 6 April, five days into the voyage, a 70-year-old Dutch man developed fever, headache, and mild diarrhoea. By 11 April, he was dead — respiratory distress, cause unknown. His body remained on board for 13 days before being removed at Saint Helena on 24 April.

His 69-year-old wife, already symptomatic, disembarked with him. She deteriorated during a flight to Johannesburg on 25 April and died at a hospital the following day. She was later confirmed positive for hantavirus by PCR on 4 May.

A third passenger — an adult male — fell ill on 24 April with fever, shortness of breath, and signs of pneumonia. He was evacuated from Ascension Island to South Africa on 27 April and remains in intensive care. His positive hantavirus test on 2 May was the first laboratory confirmation that triggered the global alert.

A German woman became the third fatality on 2 May, four days after developing symptoms consistent with pneumonia. Her body remains on the ship.

Three additional suspected cases — with high fever and gastrointestinal symptoms — remain on board under medical evaluation in Cape Verde.

A Swiss man who disembarked at Saint Helena before the outbreak was identified has since tested positive in Switzerland.

The WHO was notified on 2 May by the UK's IHR Focal Point. By 4 May, the organisation had activated three-level coordination across Cabo Verde, the Netherlands, Spain, South Africa, and the United Kingdom.

What It Actually Means

This is not COVID-19. It is not even close. But it is a genuinely unusual event that tests several weak points in the global health security apparatus simultaneously.

First, the diagnostic gap. The first passenger died on 11 April. The first laboratory confirmation came on 2 May — 21 days later. In that window, the ship made multiple port calls, passengers disembarked and flew home, and a woman died in a Johannesburg hospital without anyone connecting her death to a hantavirus cluster. The diagnostic delay was not negligence — hantavirus is rare, its early symptoms mimic common gastrointestinal illness, and the ship was in some of the most remote waters on Earth. But the gap is the story.

Second, the contact-tracing scramble. Oceanwide Expeditions confirmed that at least 29 living passengers left the ship after the first death but before the outbreak was identified. They are now self-isolating in countries including Britain and Singapore. US public health agencies in Georgia, Arizona, and California are monitoring residents who were aboard. A KLM flight attendant in Amsterdam is being tested after contact with the Dutch woman who died. Two flights linked to that woman are now part of the contact-tracing effort.

The incubation period for Andes hantavirus can stretch to six weeks — and in rare cases up to eight. The WHO's Director-General Tedros Adhanom Ghebreyesus said Thursday that "it is possible more cases will be reported." That is not alarmism. It is arithmetic.

Third, the person-to-person question. The Hondius outbreak may provide the clearest evidence yet on whether Andes hantavirus transmits between humans. A cruise ship in the South Atlantic is a controlled environment in a way that a Patagonian village is not. If sequencing confirms secondary cases among passengers who had no shared shore excursions or cabin proximity to rodent environments, the evidence for person-to-person transmission strengthens considerably. If all cases trace back to a single shore exposure in Ushuaia, the case weakens. The NICD's ongoing metagenomics and serology work will provide answers.

The Argentina Angle

Argentina is consistently ranked by the WHO as having the highest incidence of hantavirus in Latin America. The country's Health Ministry reports that the disease led to death in nearly a third of cases in the last year — up from a 15% average mortality rate over the preceding five years.

Argentine investigators, speaking anonymously to the AP, said the leading hypothesis is that the Dutch couple who died contracted the virus during a bird-watching outing near Ushuaia before boarding. The couple had travelled in South America, including Argentina, before embarking on 1 April.

Local researchers attribute the broader surge to climate change, which is expanding the range and population density of the rodent reservoirs that carry hantavirus. Warmer temperatures extend breeding seasons and increase food availability for rodent populations. The result is more rodents, carrying more virus, in more places, for more of the year. This is not a new observation — the LA Times reported Wednesday that Argentine public health researchers have been warning about this trend — but the Hondius outbreak has given it a global stage.

The Preparedness Question

The New York Times reported Thursday that the US response has been notably muted. Information about Americans aboard the ship came not from the CDC or the State Department but from the medical news publication MedPage Today. Dr. Jeanne Marrazzo, CEO of the Infectious Diseases Society of America, told Forbes that the United States is "not prepared" to handle a hantavirus outbreak, citing Trump-era cuts to the CDC and USAID, as well as the country's withdrawal from the WHO.

This matters more than usual because the FIFA World Cup 2026 opens across 11 American cities in six weeks. Dr. Krutika Kuppalli, an infectious diseases physician and former WHO official, wrote in STAT News that "not being part of the WHO, especially ahead of the World Cup, is a dangerous position."

The WHO, for its part, has been transparent and measured. Its Disease Outbreak News published on 4 May is a model of clarity: detailed case histories, a full risk assessment, explicit clinical guidance, and a clear statement that the organisation "advises against the application of any travel or trade restrictions."

Stakeholder Landscape

Directly affected: The 147 passengers and crew of the MV Hondius, particularly the three suspected cases still on board. The families of the three deceased. The 29+ passengers who disembarked early and are now under monitoring. The KLM flight attendant and passengers on two linked flights.

Second-order affected: Public health agencies in at least a dozen countries now running contact tracing. Argentina's health ministry, which must determine the source and manage domestic case surveillance. Spain, which has accepted the ship in the Canary Islands. South Africa's NICD, which confirmed the first cases and is running ongoing serology and sequencing.

Institutionally implicated: The CDC and US State Department, whose response posture is being scrutinised. The WHO, which is coordinating a multi-country response while navigating the US absence. Oceanwide Expeditions, whose decision-making between the first death and the outbreak declaration will face investigation.

Not affected despite the noise: The general public. Hantavirus is not a respiratory pandemic threat. The risk to anyone not in close contact with an infected person or rodent-infested environments in endemic areas is negligible.

Cross-Layer Implications

Climate → health. The Argentina surge is not a coincidence. Warming temperatures are expanding rodent habitats and lengthening breeding seasons. This is a slow-burn structural driver that will produce more hantavirus clusters, not fewer.

Tourism → biosecurity. Expedition cruises to remote, ecologically diverse regions create novel exposure pathways. The Hondius stopped at islands with endemic rodent populations. The extent of passenger contact with wildlife "remains undetermined," per the WHO.

Global health governance → event response. The US withdrawal from the WHO means the country is receiving information through secondary channels during an outbreak that directly involves its citizens. The World Cup in six weeks raises the stakes on every gap in the surveillance architecture.

Virology → policy. If the Hondius sequencing confirms person-to-person transmission in a rodent-free environment, the classification of Andes hantavirus as an HCID with airborne precautions will strengthen, with implications for hospital infection control protocols worldwide.

What This Means for You

If you were on the MV Hondius or had contact with someone who was: You are already being contacted by health authorities. The 45-day symptom monitoring window is real — fever, headache, gastrointestinal symptoms, or respiratory distress in that period warrant immediate medical attention with full travel history disclosure.

If you are travelling to Argentina or Chile: Hantavirus is endemic. Avoid contact with rodents and rodent droppings. Do not dry-sweep potentially contaminated areas — wet-cleaning methods only. Most routine tourism carries minimal risk.

If you are a public health practitioner: The WHO DON contains detailed clinical management guidance. Key points: no specific antiviral is approved for HCPS; ribavirin has not demonstrated effectiveness; management relies on careful fluid administration, haemodynamic monitoring, and respiratory support; early ICU transfer is critical.

If you are a general reader: This is a serious public health event that warrants attention, not alarm. The systems are working — slowly, imperfectly, but working. The diagnostic delay is concerning but explicable. The contact tracing is aggressive. The WHO's transparency is commendable.

Uncertainty Ledger

  • Source of the outbreak: The Argentine bird-watching hypothesis is leading but unconfirmed. The WHO notes that exposure could have occurred at any of the ship's multiple stops.
  • Secondary cases: The 45-day window means we will not know the full extent of transmission until mid-June at the earliest.
  • Sequencing results: Serology, sequencing, and metagenomics from the South African NICD are ongoing. These will clarify whether the outbreak strain matches known Argentine variants — and whether person-to-person transmission occurred.
  • US response posture: The CDC's operational capacity for this event is unclear. The information vacuum noted by the NYT may reflect genuine gaps or deliberate communication strategy.
  • Ship sanitation investigation: How the virus circulated on board — whether through rodent contact at a port or person-to-person transmission — remains undetermined, and the answer has implications for cruise industry biosecurity protocols.

Bottom Line

The MV Hondius outbreak is a rare event — an Andes hantavirus cluster on a cruise ship, with cases now scattered across at least five countries — that is being managed by a global health architecture that is thinner than it was two years ago. The WHO's risk assessment is low, and that assessment is probably right. Hantavirus is not a pandemic pathogen: it does not spread through casual respiratory contact, it has no asymptomatic transmission, it evolves slowly, and it is geographically constrained by its rodent hosts. The Andes strain's person-to-person transmission is real but limited, requiring close and prolonged exposure. The Epuyén outbreak was contained through aggressive contact tracing and isolation.

But the diagnostic delay, the dispersed passengers, the six-week incubation window, and the US preparedness questions combine to make this a story that will not be over for weeks. The pandemic risk is low. The diagnostic risk — that cases go unrecognised in countries with no hantavirus experience — is not. The preparedness risk — whether the global health architecture can coordinate a multi-country response to an unusual pathogen — is being tested in real time.

The systems are holding. The question is whether they would hold under a faster-moving threat.

 

Sources:

  • WHO Disease Outbreak News (4 May 2026, Tier 1)
  • WHO Hantavirus Fact Sheet (6 May 2026, Tier 1)
  • CDC About Hantavirus (4 May 2026, Tier 1)
  • UKHSA Andes Hantavirus Guidance (Tier 1)
  • GAVI: The Next Pandemic: Hantavirus? (Tier 2)
  • CNN (7 May 2026, Tier 1)
  • AP News (5–7 May 2026, Tier 1)
  • The Washington Post (7 May 2026, Tier 1)
  • Forbes (7 May 2026, Tier 2)
  • The New York Times (7 May 2026, Tier 1)
  • STAT News (5 May 2026, Tier 2)
  • USA Today (7 May 2026, Tier 2)
  • Los Angeles Times (6 May 2026, Tier 2)
  • The Guardian (7 May 2026, Tier 2)
  • Toledo et al., "Evidence for Human-to-Human Transmission of Hantavirus" Clinical Microbiology and Infection (2022, Tier 1)
  • Wikipedia: Hantavirus Pulmonary Syndrome (Tier 3)
  • Cleveland Clinic: Hantavirus Pulmonary Syndrome (Tier